Promedior Inc has begun a Phase 2 trial of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with idiopathic pulmonary fibrosis (IPF).

This randomized, double-blind, placebo-controlled Phase 2 study is designed to determine the efficacy and safety of PRM-151 in approximately 117 patients with IPF.

PRM-151 targets the underlying fibrotic pathology of IPF. A randomized, double-blind, placebo controlled Phase 1b multiple ascending dose study of PRM-151 in patients with IPF assessed changes in Forced Vital Capacity (FVC), and changes in interstitial lung disease features were explored retrospectively by quantitative imaging analysis of high resolution CT (HRCT).